摘要
目的:对比多吉美单药治疗肝癌与联合介入治疗的效果.方法:回顾性分析20例系统服用多吉美的肝癌患者,其中单药治疗的7例,联合介入治疗的13例,随访方式采用门诊随访及住院随访,随访时间7-28mo.主要研究终点为肿瘤反应率和肿瘤进展时间.结果:20例患者中,CR4例,PR10例,SD4例,PD2例,其中单药治疗组CR0例,PR3例,SD2例,PD2例;单药治疗组及联合治疗组的中位肿瘤进展时间分别为16及48wk.结论:多吉美联合肝癌介入治疗可增加肿瘤反应率,延长肿瘤进展时间.
AIM：To analyze the efficacy of Nexavar alone and in combination with interventional therapy for hepatocellular carcinoma.METHODS：Twenty hepatocellular carcinoma patients,including 7 receiving Nexavar monotherapy and 13 receiving Nexavar in combination with interventional therapy,were retrospectively analyzed.All patients were followed up for 7-28 months.The primary study endpoint was tumor response rate and time to tumor progression （TTP）.RESULTS：Of 20 patients,4 achieved a complete response （CR）,10 achieved a partial response （PR）,4 had stable disease （SD）,and 2 had progressive disease （PD）.In the Nexavar monotherapy group,no patients experienced a CR,3 patients experienced a PR,two patients had SD,and 2 patients had PD.The median time to tumor progression was 16 and 48 weeks in the monotherapy group and the combination treatment group,respectively.CONCLUSION：Nexavar in combination with interventional therapy can increase the tumor response rate and prolong the time to tumor progression in patients with hepatocellular carcinoma.
出处
《世界华人消化杂志》
CAS
北大核心
2010年第5期517-520,共4页
World Chinese Journal of Digestology
关键词
多吉美
介入治疗
肝癌
疗效
Nexavar
Interventional therapy
Hepatocellular carcinoma
Efficacy
